RS Research announces that the phase 1 study of RS-0139 is now part of the ESMO Congress 2026 scientific programme

The phase 1 study of RS-0139 is now part of the ESMO Congress 2026 scientific programme, to be held in Madrid at 23-27 October 2026:

“First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors”

 

Further information will be available after the ESMO Congress 2026.

RS Research develops investigational programs. Content on this website is for general informational purposes only, does not provide medical advice and relates to products that are not approved for general use. Full disclaimer and important information ↗